Randomized Controlled Trial of Vaginal Cryotherapy for Pelvic Floor Myofascial Pain
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03885791 |
|
Recruitment Status :
Recruiting
First Posted : March 22, 2019
Last Update Posted : May 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pelvic Floor Myofascial Pain Pelvic Pain Myofascial Pain | Device: vaginal cryotherapy | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 132 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Controlled Trial of Vaginal Cryotherapy for Pelvic Floor Myofascial Pain |
| Actual Study Start Date : | March 22, 2019 |
| Estimated Primary Completion Date : | December 30, 2021 |
| Estimated Study Completion Date : | December 30, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vaginal cryotherapy - intervention
The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a "slushy" consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer.
|
Device: vaginal cryotherapy
Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion. Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application. |
|
Placebo Comparator: Vaginal cryotherapy - control
The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
|
Device: vaginal cryotherapy
Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion. Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application. |
- change in myofascial pain score [ Time Frame: 10-15 minutes (Pre- to post-treatment) ]Primary outcome is change in pelvic floor myofascial pain scores at each site (bilateral OI and LA) as measured on a 0-10 visual pain rating scale where 0 indicates no pain on palpation and 10 indicates 'worst pain imaginable' on palpation.
- Pelvic Floor Distress Inventory-20 [ Time Frame: 2 weeks ]Short form of the validated questionnaire to assess presence and degree of bother of common pelvic floor symptoms
- Pelvic Floor Impact Questionnaire-7 [ Time Frame: 2 weeks ]Short form of the validated questionnaire to assess impact of pelvic floor symptoms on daily activities
- Prolapse and Incontinence Sexual Questionnaire [ Time Frame: 2 weeks ]Short form of the validated questionnaire to assess the impact of pelvic floor symptoms on sexual activity
- Urogenital Distress Inventory [ Time Frame: 2 weeks ]Validated questionnaire to assess presence and degree of bother of lower urinary tract symptoms
- Lower Urinary Tract Symptoms (LUTS) Tool [ Time Frame: 2 weeks ]Validated questionnaire to assess lower urinary tract symptoms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult (>18yo)
- Women
- Patients found to have pelvic floor myofascial pain of at least 4/10 in severity at any of the four sites (right obturator internus, right levator ani, left levator ani, left obturator internus)
Exclusion Criteria:
- Age <18
- Non-English speaking
- Current diagnosis of dementia
- Limited physical mobility that would prevent full participation in pelvic floor PT.
- Prior use of vaginal cryotherapy
- Chief complaint or known history of pelvic pain
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885791
| Contact: Jerry Lowder, MD | 3147471402 | lowderj@wustl.edu | |
| Contact: Haidy Morsy, MD | 314-273-1905 | h.morsy@wustl.edu |
| United States, Missouri | |
| Center for Outpatient Health/Washington University in St. Louis | Recruiting |
| Saint Louis, Missouri, United States, 63110 | |
| Contact: Jerry Lowder, MD 314-747-1402 lowderj@wustl.edu | |
| Contact: Haidy Morsy, MD 314-273-1905 h.morsy@wustl.edu | |
Documents provided by Washington University School of Medicine:
| Responsible Party: | Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT03885791 |
| Other Study ID Numbers: |
201901209 |
| First Posted: | March 22, 2019 Key Record Dates |
| Last Update Posted: | May 5, 2021 |
| Last Verified: | May 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Myofascial Pain Syndromes Pelvic Pain Pain |
Neurologic Manifestations Muscular Diseases Musculoskeletal Diseases |

